Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 3, 2004, Pages 351-358

  Sunkara, Gangadhar ^a   Ayalasomayajula, Surya P ^a   Rao, Cheruku S ^a   Vennerstrom, Jonathan L ^a   DeRuiter, Jack ^b   Kompella, Uday B ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b AUBURN UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; N [4 (BENZOYLAMINO)PHENYLSULFONYL]GLYCINE; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CILIARY BODY; CONCENTRATION RESPONSE; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IRIS; KIDNEY PARENCHYMA; LENS; MALE; NONHUMAN; PLASMA PROTEIN BINDING; RABBIT; RAT; RETINA; TISSUE DISTRIBUTION; ULTRACENTRIFUGATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ALDEHYDE REDUCTASE; ANIMALS; BIOLOGICAL AVAILABILITY; EYE; GLYCINE; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MALE; PROTEIN BINDING; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SULFONES; TISSUE DISTRIBUTION;

EID: 1642278784     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357022908     Document Type: Article

References (30)

1. Akagi, Y., Kador, P. F., Kuwabara, T., Kinoshita, J. H. (1983) Aldose reductase localization in human retinal mural cells. Invest. Ophthalmol. Vis. Sci. 24: 1516-1519
2. Alder, V. A., Su, E. N., Yu, D. Y., Cringle, S., Yu, P. (1998) Overview of studies on metabolic and vascular regulatory changes in early diabetic retinopathy. Aust. N. Z. J. Ophthalmol. 26: 141-148
3. Aukunuru, J. V., Sunkara, G., Bandi, N., Thoreson, W. B., Kompella, U. B. (2001) Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm. Res. 18: 565-572
4. Aukunuru, J. V., Sunkara, G., Ayalasomayajula, S. P., DeRuiter, J., Clark, R. C., Kompella, U. B. (2002) A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm. Res. 19: 278-285
5. Bron, A. J., Sparrow, J., Brown, N. A., Harding, J. J., Blakytny, R. (1993) The lens in diabetes. Eye 7 (Pt 2): 260-275
6. Conrad, S. M., Doughty, C. C. (1982) Comparative studies on aldose reductase from bovine, rat and human lens. Biochim. Biophys. Acta 708: 348-357
7. Costantino, L., Rastelli, G., Vianello, P., Cignarella, G., Barlocco, D. (1999) Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches. Med Res. Rev. 19: 3-23
8. Datiles, M. B., Kador, P. F., Fukui, H. N., Hu, T. S., Kinoshita, J. H. (1983) Corneal re-epithelialization in galactosemic rats. Invest. Ophthalmol. Vis. Sci. 24: 563-569
9. Davis, R. A., Mayfield, C. A., Aull, J. L., DeRuiter, J. (1993) Enzyme selectivity analyses of arylsulfonylamino acid aldose reductase inhibitors. J. Enzyme Inhib. 7: 87-96
10. Fagius, J., Jameson, S. (1981) Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study. J. Neurol. Neurosurg. Psychiatry 44: 991-1001
11. Handelsman, D. J., Turtle, J. R. (1981) Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 30: 459-464
12. Jaspan, J. B., Herold, K., Bartkus, C. (1985) Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Am. J. Med. 79: 24-37
13. Krentz, A. J., Honigsberger, L., Ellis, S. H., Hardman, M., Nattrass, M. (1992) A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet. Med. 9: 463-468
14. Ljubimov, A. V., Burgeson, R. E., Butkowski, R. J., Couchman, J. R., Wu, R. R., Ninomiya, Y., Sado, Y., Maguen, E., Nesburn, A. B., Kenney, M. C. (1996a) Extracellular matrix alterations in human corneas with bullous keratopathy. Invest. Ophthalmol. Vis. Sci. 37: 997-1007
15. Ljubimov, A. V., Burgeson, R. E., Butkowski, R. J., Couchman, J. R., Zardi, L., Ninomiya, Y., Sado, Y., Huang, Z. S., Nesburn, A. B., Kenney, M. C. (1996b) Basement membrane abnormalities in human eyes with diabetic retinopathy. J. Histochem. Cytochem. 44: 1469-1479
16. Macleod, A. F., Boulton, A. J., Owens, D. R., Van Rooy, P., Van Gerven, J. M., Macrury, S., Scarpello, J. H., Segers, O., Heller, S. R., Van Der Veen, E. A. (1992) A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group. Diabetes Metab. 18: 14-20
17. Mayfield, C. A., DeRuiter, J. (1987) Novel inhibitors of rat lens aldose reductase: N-[[(substituted amino)phenyl]sulfonyl] glycines. J. Med. Chem. 30: 1595-1598
18. Oates, P. J., Mylari, B. L. (1999) Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Expert Opin. Investig. Drugs 8: 2095-2119
19. Pfeifer, M. A., Schumer, M. P., Gelber, D. A. (1997) Aldose reductase inhibitors: The end of an era or the need for different trial designs? Diabetes 46 (Suppl. 2): S82-S89
20. Pitts, N. E., Vreeland, F., Shaw, G. L., Peterson, M. J., Mehta, D. J., Collier, J., Gundersen, K. (1986) Clinical experience with sorbinil - an aldose reductase inhibitor. Metabolism 35: 96-100
21. Sarges, R., Schnur, R. C., Belletire, J. L., Peterson, M. J. (1988) Spiro hydantoin aldose reductase inhibitors. J. Med. Chem. 31: 230-243
22. Sato, S., Kador, P. F. (1990) Inhibition of aldehyde reductase by aldose reductase inhibitors. Biochem. Pharmacol. 40: 1033-1042
23. Sunkara, G., Kompella, U. B. (2003) Transport processes in ocular epithelia. In: Mitra, A. K. (ed.) Ophthalmic drug delivery. Marcel Dekker, New York, pp 13-58
24. Sunkara, G., Deruiter, J., Clark, C. R., Kompella, U. B. (2000) In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor. J. Pharm. Pharmacol. 52: 1113-1122
25. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986
26. Urtti, A., Salminen, L. (1993) Animal pharmacokinetic studies. In: Mitra, A. K. (ed.) Ophthalmic drug delivery systems. Marcel Dekker, New York, pp 317-375
27. Yabe-Nishimura, C. (1998) Aldose reductase in glucose toxicity: A potential target for the prevention of diabetic complications. Pharmacol. Rev. 50: 21-33
28. Yamaoka, K., Nakagawa, T., Uno, T. (1978) Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6: 547-558
29. Zhang, Y., Han, H., Elmquist, W. F., Miller,. D. W. (2000) Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876: 148-153
30. Ziegler, D., Mayer, P., Rathmann, W., Gries, F. A. (1991) One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res. Clin. Pract. 14: 63-73